ATE374785T1 - Gpib-gebundenes konstrukt und verwendungen davon - Google Patents
Gpib-gebundenes konstrukt und verwendungen davonInfo
- Publication number
- ATE374785T1 ATE374785T1 AT01908262T AT01908262T ATE374785T1 AT E374785 T1 ATE374785 T1 AT E374785T1 AT 01908262 T AT01908262 T AT 01908262T AT 01908262 T AT01908262 T AT 01908262T AT E374785 T1 ATE374785 T1 AT E374785T1
- Authority
- AT
- Austria
- Prior art keywords
- gpib
- present
- lipid
- lipid complex
- conjugate
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 abstract 7
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000003966 vascular damage Effects 0.000 abstract 1
- 231100000216 vascular lesion Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000057449 | 2000-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE374785T1 true ATE374785T1 (de) | 2007-10-15 |
Family
ID=18578236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01908262T ATE374785T1 (de) | 2000-03-02 | 2001-03-02 | Gpib-gebundenes konstrukt und verwendungen davon |
Country Status (7)
Country | Link |
---|---|
US (1) | US6926884B2 (de) |
EP (1) | EP1262490B1 (de) |
AT (1) | ATE374785T1 (de) |
AU (1) | AU2001236062A1 (de) |
DE (1) | DE60130741T2 (de) |
ES (1) | ES2291295T3 (de) |
WO (1) | WO2001064743A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2370690A1 (en) * | 1999-04-20 | 2000-10-26 | The University Of British Columbia | Cationic peg-lipids and methods of use |
US7459169B2 (en) * | 2002-10-21 | 2008-12-02 | Allvivo, Inc. | Surface coating comprising bioactive compound |
AU2003280761B2 (en) * | 2002-11-15 | 2009-10-01 | Nipro Corporation | Liposome |
EP1591451A4 (de) * | 2003-02-06 | 2009-09-02 | Univ Keio | Peptidkonjugat |
JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
CN101389356B (zh) | 2006-01-06 | 2012-09-05 | 武冈真司 | 药物输送物质 |
JP5216219B2 (ja) * | 2006-01-06 | 2013-06-19 | 真司 武岡 | 薬物運搬体 |
US20080015145A1 (en) * | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
CA2600220C (en) * | 2006-09-07 | 2014-12-09 | Canadian Blood Services | Surface cross-linked lipidic particles, methods of production and uses therefor |
US20080241233A1 (en) * | 2007-03-28 | 2008-10-02 | Portola Pharmaceuticals, Inc. | Targeted delivery and expression of procoagulant hemostatic activity |
EP3538546A1 (de) | 2016-11-14 | 2019-09-18 | Novartis AG | Zusammensetzungen, verfahren und therapeutische verwendungen im zusammenhang mit fusogenem protein minion |
CN116019960A (zh) | 2018-10-17 | 2023-04-28 | 东丽株式会社 | 止血材料 |
CN112823149B (zh) | 2018-10-17 | 2024-03-08 | 东丽株式会社 | 羧酸型脂质、含有该羧酸型脂质的脂质颗粒和脂质膜 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200510A (en) * | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
US5340727A (en) * | 1987-11-17 | 1994-08-23 | The Scripps Research Institute | GPIbα fragments and recombinant DNA expression vectors |
US5914231A (en) * | 1995-08-17 | 1999-06-22 | Universiteit Utrecht Introgene B.V. | Poly(organo)phosphazenes for use in synthetic transfection systems |
JP3735921B2 (ja) | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | GPIb・脂質複合体およびその用途 |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
-
2001
- 2001-03-02 AT AT01908262T patent/ATE374785T1/de not_active IP Right Cessation
- 2001-03-02 WO PCT/JP2001/001635 patent/WO2001064743A1/ja active IP Right Grant
- 2001-03-02 DE DE60130741T patent/DE60130741T2/de not_active Expired - Lifetime
- 2001-03-02 EP EP01908262A patent/EP1262490B1/de not_active Expired - Lifetime
- 2001-03-02 ES ES01908262T patent/ES2291295T3/es not_active Expired - Lifetime
- 2001-03-02 US US10/220,610 patent/US6926884B2/en not_active Expired - Fee Related
- 2001-03-02 AU AU2001236062A patent/AU2001236062A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2291295T3 (es) | 2008-03-01 |
EP1262490A4 (de) | 2005-06-22 |
US20030113262A1 (en) | 2003-06-19 |
AU2001236062A1 (en) | 2001-09-12 |
DE60130741D1 (de) | 2007-11-15 |
EP1262490A1 (de) | 2002-12-04 |
EP1262490B1 (de) | 2007-10-03 |
DE60130741T2 (de) | 2008-07-03 |
WO2001064743A1 (fr) | 2001-09-07 |
US6926884B2 (en) | 2005-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE374785T1 (de) | Gpib-gebundenes konstrukt und verwendungen davon | |
FR13C0021I2 (fr) | Conjugates d'exendin-4 et leur utilisation medicale | |
DOP2000000114A (es) | Oxazolidinonas substituidas y su uso | |
EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
DE60135780D1 (de) | Aspirin enthaltende medizinische zusammensetzungen | |
ATE490277T1 (de) | Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon | |
CY1106886T1 (el) | Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων | |
WO2001010907A3 (en) | Therapeutic polypeptides and methods for using same | |
DK1392254T3 (da) | Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler | |
MA26230A1 (fr) | Agents antidysrythmiques administres par voie vaginale utilises pour traiter les douleurs pelviennes et la sterilite | |
DE68925034T2 (de) | Konjugate zur knochenbilddarstellung und therapie von knochenkrebs. | |
BR9810832B1 (pt) | composição farmacêutica contendo como princìpios ativos vitamina d associada a um sal de cálcio, e, processos para a preparação de uma composição farmacêutica, para o tratamento de deficiências nutricionais de cálcio e vitamina d na velhice e para reduzir a perda de tecido ósseo ligada à idade e para evitar fraturas femurais e outras fraturas não vertebrais. | |
AR033658A1 (es) | Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d | |
DK0383417T3 (da) | Flagmusespyt-plasminogenaktivator v-PAalfa1 | |
FI952593A0 (fi) | Hyytymistä estävä aine | |
ATE498305T1 (de) | Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen | |
Huh et al. | Autologous bone marrow mesenchymal cell induced chondrogenesis for the treatment of osteoarthritis of knee | |
DE50009745D1 (de) | Gewinnung von lipoproteinen aus körperflüssigkeiten | |
Leung et al. | The use of prostaglandins as local antithrombotic agents in microvascular surgery | |
Samos et al. | Review of the pharmacology of the emerging possibilities of the direct oral anticoagulants' reversal | |
Israel et al. | 12 Antithrombotic therapy for coronary artery disease and valvular heart disease | |
Cho et al. | Reduction labioplasty of female genitalia | |
UA9703A (uk) | Антипротеіназний засіб | |
JP2000119194A (ja) | サイトカイン産生促進剤 | |
BR0102864A (pt) | Compostos, composições farmacêuticas, processos para a fabricação de compostos e de composições farmacêuticas, e, uso de um ou mais compostos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |